HSBC Holdings plc reissued their reduce rating on shares of AstraZeneca plc (LON:AZN) in a research report released on Monday, May 15th. They currently have a GBX 4,200 ($53.13) price target on the biopharmaceutical company’s stock.
Several other research analysts have also recently commented on AZN. Deutsche Bank AG lowered their target price on shares of AstraZeneca plc from GBX 6,000 ($75.90) to GBX 5,500 ($69.58) and set a buy rating on the stock in a report on Monday, February 6th. Shore Capital reaffirmed a sell rating on shares of AstraZeneca plc in a report on Sunday, April 2nd. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($49.34) target price on shares of AstraZeneca plc and gave the stock a sell rating in a report on Thursday, May 11th. Bryan, Garnier & Co reaffirmed a buy rating and set a GBX 5,400 ($68.31) target price on shares of AstraZeneca plc in a report on Tuesday, February 28th. Finally, Berenberg Bank decreased their price objective on shares of AstraZeneca plc from GBX 5,500 ($69.58) to GBX 5,450 ($68.94) and set a buy rating on the stock in a research note on Tuesday, February 21st. Five research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have given a buy rating to the company. AstraZeneca plc currently has an average rating of Hold and an average target price of GBX 5,121.80 ($64.79).
AstraZeneca plc (AZN) traded up 0.02% during midday trading on Monday, reaching GBX 5284.00. The company’s stock had a trading volume of 3,878,930 shares. AstraZeneca plc has a 52 week low of GBX 3,680.00 and a 52 week high of GBX 5,505.00. The firm’s market cap is GBX 66.90 billion. The firm has a 50 day moving average price of GBX 5,087.18 and a 200-day moving average price of GBX 4,684.86.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.